<DOC>
	<DOC>NCT00667992</DOC>
	<brief_summary>This study is being carried out to see if budesonide with HFA is effective, safe and well tolerated compared with budesonide CFC. Budesonide HFA has been already given in other research studies, in both healthy volunteers and subjects with asthma.</brief_summary>
	<brief_title>Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients suffering from stable, persistent, mild to moderate asthma as defined by Global Initiative for Asthma (GINA) Guidelines and for whom FEV1 &gt; 60 % ICS taking ≤ 1000 μg BDP per day, or equivalent Methacholine PC20 &lt; 4 mg/mL Known or suspected hypersensitivity to budesonide or any other constituents of the budesonide HFA pMDI or budesonide CFC pMDI. Currently a smoker or who has ceased smoking within 6 months of Visit 1. Exacerbations of asthma requiring oral steroids, hospitalisation or change in asthma therapy in the previous three months. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or bronchiectasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Asthma hyperreactivity</keyword>
</DOC>